NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: It has been successfully used for the treatment of CML, as well as gastrointestinal stromal tumors, which are typically driven by gain-of-function mutations in the KIT tyrosine kinase receptor [66].